Peripheral Biomarkers of Parkinson’s Disease Progression and Pioglitazone Effects

David K. Simon, Tanya Simuni, Jordan J. Elm, Joanne Clark, Allison K. Graebner, Liana Baker, Susan Rebecca Dunlop, Marina E. Emborg, Cornelia Kamp, John C. Morgan,

Journal of Parkinson s Disease · 2015 · 30 citations · 27 references

DOIFull text

Open access

Concepts

Abstract

Pioglitazone, an oral hypoglycemic agent, recently failed to show promise as a disease-modifying agent in a 44-week phase 2 placebo-controlled study in 210 Parkinson's disease (PD) subjects. We analyzed peripheral biomarkers, including leukocyte PGC-1α and target gene expression, plasma interleukin 6 (IL-6) as a marker of inflammation, and urine 8-hydroxydeoxyguanosine (8OHdG) as a marker of oxidative DNA damage. Baseline or changes from baseline in biomarker levels were not associated with the rate of progression of PD. Pioglitazone did not significantly alter biomarker levels. Other agents that more effectively target these mechanisms remain of potential interest as disease modifying therapies in PD.

References

27